Fragmentation in US health care delivery streams and shortcomings in formal quality measures mean that transparency could be more useful to policymakers and regulators than patients.
AMA J Ethics. 2022;24(11):E1075-1082. doi:
10.1001/amajethics.2022.1075.
Dr Kevin Schulman joins Ethics Talk to discuss his article, coauthored with Dr Barak Richman: “Informed Consent as a Means of Acknowledging and Avoiding Financial Toxicity as Iatrogenic Harm.”
Dr Jing Li joins Ethics Talk to discuss her article, coauthored with Dr Robert Tyler Braun, Sophia Kakarala, and Dr Holly G. Prigerson: “How Should Cost-Informed Goals of Care Decisions Be Facilitated at Life’s End?”
Sarosh Nagar joins Ethics Talk to discuss his article, coauthored with Drs Leah Z. Rand and Aaron S. Kesselheim: “What Should US Policymakers Learn From International Drug Pricing Transparency Strategies?”
Annika Brakebill, A. Mark Fendrick, MD, and Jeffrey T. Kullgren, MD, MS, MPH
These key steps are ones health sector stakeholders should take to help patients and clinicians use pricing information to inform health decision making.
AMA J Ethics. 2022;24(11):E1034-1039. doi:
10.1001/amajethics.2022.1034.
Sarosh Nagar, Leah Z. Rand, PhD, and Aaron S. Kesselheim, MD, JD, MPH
This article analyzes differences in prescription drug pricing transparency practices among 3 Organisation of Economic Co-operation and Development member nations.
AMA J Ethics. 2022;24(11):E1083-1090. doi:
10.1001/amajethics.2022.1083.
